TY - JOUR
T1 - Paediatric mycosis fungoides – characteristics, management and outcomes with particular focus on the folliculotropic variant
AU - Reiter, O.
AU - Amitay-Laish, I.
AU - Oren-Shabtai, M.
AU - Feinmesser, M.
AU - Ben-Amitai, D.
AU - Hodak, E.
N1 - Publisher Copyright:
© 2022 European Academy of Dermatology and Venereology.
PY - 2022/5
Y1 - 2022/5
N2 - Background: The literature on paediatric mycosis fungoides (MF) and especially its folliculotropic variant (FMF) is sparse. Objectives: To describe the clinical manifestations, treatments, outcomes and long-term course of paediatric MF, including FMF. Methods: A retrospective analysis was conducted of all consecutive MF patients diagnosed at ≤18 years attending two medical centres in 1995–2015. Results: The cohort included 71 patients, all but two of whom had early-stage disease: hypopigmented (55%), folliculotropic (42%) and classical MF (39%), alone or in combination. The head and neck area were involved in 43% of patients with early-stage FMF compared to 12% of the non-FMF group (P = 0.004). There was no difference in the involvement of other body areas between the groups. Pruritus, although mild, was more often recorded among patients with early-stage FMF compared to non-FMF (58% vs. 29%, respectively, P = 0.02). Complete response (CR) was achieved in 60 of the 69 patients with early-stage MF (87%) after an average of 1.8 treatment modalities. NBUVB was the most administered treatment to non-FMF patients with CR rates of 63% vs. 29% of FMF patients (P = 0.04). Systemic/bath PUVA and UVA+NBUVB were the most administered treatments to FMF patients with CR rates of 60% vs. 81% for non-FMF patients (P = 0.17). During a mean follow-up of 9.2 years (range 1–24), stage progression was observed in four (6%) of the patients with early-stage disease, two of whom (all FMF) to advanced stage. Conclusions: Paediatric MF presents as an early-stage disease with over-representation of hypopigmented and FMF variants. NBUVB and UVA-based therapies yield good response rates in non-FMF and FMF patients, respectively. Disease course is indolent, and even on relatively long follow-up, it has a very low progression rate from early to advanced-stage disease, occurring in patients with FMF. We propose a treatment algorithm for paediatric MF.
AB - Background: The literature on paediatric mycosis fungoides (MF) and especially its folliculotropic variant (FMF) is sparse. Objectives: To describe the clinical manifestations, treatments, outcomes and long-term course of paediatric MF, including FMF. Methods: A retrospective analysis was conducted of all consecutive MF patients diagnosed at ≤18 years attending two medical centres in 1995–2015. Results: The cohort included 71 patients, all but two of whom had early-stage disease: hypopigmented (55%), folliculotropic (42%) and classical MF (39%), alone or in combination. The head and neck area were involved in 43% of patients with early-stage FMF compared to 12% of the non-FMF group (P = 0.004). There was no difference in the involvement of other body areas between the groups. Pruritus, although mild, was more often recorded among patients with early-stage FMF compared to non-FMF (58% vs. 29%, respectively, P = 0.02). Complete response (CR) was achieved in 60 of the 69 patients with early-stage MF (87%) after an average of 1.8 treatment modalities. NBUVB was the most administered treatment to non-FMF patients with CR rates of 63% vs. 29% of FMF patients (P = 0.04). Systemic/bath PUVA and UVA+NBUVB were the most administered treatments to FMF patients with CR rates of 60% vs. 81% for non-FMF patients (P = 0.17). During a mean follow-up of 9.2 years (range 1–24), stage progression was observed in four (6%) of the patients with early-stage disease, two of whom (all FMF) to advanced stage. Conclusions: Paediatric MF presents as an early-stage disease with over-representation of hypopigmented and FMF variants. NBUVB and UVA-based therapies yield good response rates in non-FMF and FMF patients, respectively. Disease course is indolent, and even on relatively long follow-up, it has a very low progression rate from early to advanced-stage disease, occurring in patients with FMF. We propose a treatment algorithm for paediatric MF.
UR - http://www.scopus.com/inward/record.url?scp=85125487739&partnerID=8YFLogxK
U2 - 10.1111/jdv.17971
DO - 10.1111/jdv.17971
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35080278
AN - SCOPUS:85125487739
SN - 0926-9959
VL - 36
SP - 671
EP - 679
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 5
ER -